Search by Drug Name or NDC
NDC 49702-0202-18 COMBIVIR 150; 300 mg/1; mg/1 Details
COMBIVIR 150; 300 mg/1; mg/1
COMBIVIR is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is LAMIVUDINE; ZIDOVUDINE.
MedlinePlus Drug Summary
The combination of lamivudine and zidovudine is used along with other medications to treat human immunodeficiency virus (HIV) infection. Lamivudine and zidovudine are in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). They work by decreasing the amount of HIV in the blood. Although the combination of lamivudine and zidovudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 49702-0202-18Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Lamivudine and Zidovudine
Product Information
| NDC | 49702-0202 |
|---|---|
| Product ID | 49702-202_9c13ddca-9cd4-4460-a16a-68da944ab01d |
| Associated GPIs | 12109902500320 |
| GCN Sequence Number | 034186 |
| GCN Sequence Number Description | lamivudine/zidovudine TABLET 150-300 MG ORAL |
| HIC3 | W5L |
| HIC3 Description | ANTIVIRALS, HIV-SPEC., NUCLEOSIDE ANALOG, RTI COMB |
| GCN | 89621 |
| HICL Sequence Number | 014014 |
| HICL Sequence Number Description | LAMIVUDINE/ZIDOVUDINE |
| Brand/Generic | Brand |
| Proprietary Name | COMBIVIR |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | lamivudine and zidovudine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 150; 300 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | LAMIVUDINE; ZIDOVUDINE |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosi |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA020857 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0202-18 (49702020218)
| NDC Package Code | 49702-202-18 |
|---|---|
| Billing NDC | 49702020218 |
| Package | 60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18) |
| Marketing Start Date | 2010-10-19 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |